{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:52:49Z","timestamp":1793645569251,"version":"4.5.1"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:00:00Z","timestamp":1728691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:00:00Z","timestamp":1728691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Translational Research Grant of NCRCH","award":["KYC2202004E"],"award-info":[{"award-number":["KYC2202004E"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-024-01612-y","type":"journal-article","created":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T11:01:51Z","timestamp":1728730911000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Increased Epstein\u2012Barr virus reactivation following prophylaxis for cytomegalovirus infection after haploidentical haematopoietic stem cell transplantation"],"prefix":"10.1186","volume":"17","author":[{"given":"Xin","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengli","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aining","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,12]]},"reference":[{"issue":"25","key":"1612_CR1","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","volume":"377","author":"M Francisco","year":"2017","unstructured":"Francisco M, Per L, Roy C, Johan M, Sanjeet D, Rafael D, et al. Letermovir Prophylaxis for Cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377(25):2433\u201344.","journal-title":"N Engl J Med"},{"key":"1612_CR2","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/leu.2011.26","volume":"25","author":"Z Peric","year":"2011","unstructured":"Peric Z, Cahu X, Chevallier P, Brissot E, Malard F, Guillaume T, et al. Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation. Leukemia. 2011;25:932\u20138.","journal-title":"Leukemia"},{"key":"1612_CR3","doi-asserted-by":"crossref","unstructured":"Styczynski J, Velden W, Fox CP, Engelhard D, Camara R, Cordonnier C et al. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016;101:803\u2009\u2013\u200911.","DOI":"10.3324\/haematol.2016.144428"},{"key":"1612_CR4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/tid.12061","volume":"15","author":"F Patriarca","year":"2013","unstructured":"Patriarca F, Medeot M, Isola M, Battista ML, Sperotto A, Pipan C, et al. Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell pre-emptive rituximab treatment for Epstein\u2013Barr virus reactivation after allogeneic transplantation treated with preemptive rituximab. Transpl Infect Dis. 2013;15:259\u201367.","journal-title":"Transpl Infect Dis"},{"key":"1612_CR5","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.1182\/blood-2009-07-143545","volume":"114","author":"HE Heslop","year":"2009","unstructured":"Heslop HE. How I treat EBV lymphoproliferation. Blood. 2009;114:4002\u20138.","journal-title":"Blood"},{"key":"1612_CR6","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1182\/blood-2003-12-4287","volume":"103","author":"HJ Wagner","year":"2004","unstructured":"Wagner HJ, Cheng YC, Huls MH, Gee AP, Kuehnle I, Krance RA, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood. 2004;103:3979\u201381.","journal-title":"Blood"},{"issue":"3","key":"1612_CR7","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41409-019-0699-6","volume":"55","author":"S Nicolas","year":"2020","unstructured":"Nicolas S, Myriam L, In\u00e8s B, Olivier P, Agn\u00e8s B, Florent M, et al. Pre-emptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes. Bone Marrow Transpl. 2020;55(3):586\u201394.","journal-title":"Bone Marrow Transpl"},{"key":"1612_CR8","doi-asserted-by":"crossref","unstructured":"Chen F, Depei W, Tao T, Gong W, Chunmei Y, Xiaowen T et al. Weekly Low-Dose Rituximab as the Preemptive Management of Epstein-Barr Virus Reactivation after Allogeneic hematopoietic stem cell transplantation: a Novel Strategy?[J].Blood, 2015, 126(23):3158\u20133158.","DOI":"10.1182\/blood.V126.23.3158.3158"},{"key":"1612_CR9","doi-asserted-by":"crossref","unstructured":"Elisa G, Oscar B, Anna C, Federica Z, Luana B, Daniela C et al. Human Cytomegalovirus-Specific T-Cell Reconstitution and Late-Onset Cytomegalovirus Infection in Hematopoietic Stem Cell Transplantation Recipients following Letermovir Prophylaxis. Transplantation and Cellular Therapy 28 (2022) 211.e1-211.e9.","DOI":"10.1016\/j.jtct.2022.01.008"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01612-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-024-01612-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01612-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T23:04:02Z","timestamp":1728774242000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-024-01612-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,12]]},"references-count":9,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1612"],"URL":"https:\/\/doi.org\/10.1186\/s13045-024-01612-y","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,12]]},"assertion":[{"value":"13 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study based on the data from the database of the First Affiliated Hospital of Soochow University, which was established according to the European Society for Blood and Marrow Transplantation (EBMT) registry. The study was approved by the Data Management Committee of the TRUMP and the institutional ethics committee of First Affiliated Hospital of Soochow University (2024\u2009\u2212\u2009367).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"94"}}